NCT04184947View on ClinicalTrials.gov

Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

CompletedOBSERVATIONAL
Enrollment

10,000

Participants

Timeline

Start Date

March 1, 2014

Primary Completion Date

December 31, 2018

Study Completion Date

February 29, 2020

Conditions
Type 2 Diabetes
Interventions
DRUG

SGLT2 inhibitor

New prescription of a SGLT-2 inhibitor (dapagliflozin, empagliflozin or canagliflozin) at any dosage during routine clinical practice

DRUG

GLP-1 receptor agonist

New prescription of a GLP-1 receptor agonisty (exenatide, liraglutide, lixisenatide, dulaglutide) at any dosage during routine clinical practice

Trial Locations (1)

35128

Division of Metabolic Diseases, University Hospital of Padova, Padua

All Listed Sponsors
lead

University of Padova

OTHER

NCT04184947 - Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists | Biotech Hunter | Biotech Hunter